Back to Resource Hub Case Study

Analytics Insights Improve Quality of Assessment Administration

In a Phase III schizophrenia trial, a global pharmaceutical sponsor faced the challenge of ensuring proper administration of the complex Positive and Negative Syndrome Scale (PANSS) across 45+ sites with 250 patients, where assessment quality directly impacts primary endpoint reliability.

This demanding scenario required systematic monitoring of a challenging patient population and complex clinical outcome assessment, where raters must spend sufficient time to accurately elicit information for confident scoring of the primary efficacy outcome measure.

The solution? Signant's PureSignal Analytics deployed specialized analytics to evaluate PANSS duration patterns across sites, compare individual site and rater performance against established benchmarks, and identify interviews that could indicate inadequate assessment quality.

The results? Early identification of at-risk administration patterns and successful implementation of targeted interventions including rater contact and retraining, significantly improving endpoint data quality throughout the trial.

The approach also helped validate the use of duration-based analytics in complex psychiatric assessments, proving that systematic monitoring of assessment administration can detect and remediate quality issues before they compromise primary endpoint reliability.

See how Signant's PureSignal Analytics solution enabled rapid detection of potential COA administration errors, provided targeted remediation strategies, and delivered systematic quality assurance for this challenging schizophrenia trial's complex primary efficacy outcome measure.

 

Get notified on new marketing insights

Here mention the benefits of subscribing